GABA Agonists
GABA Antagonists
GABA Agents
GABA Modulators
Receptors, GABA-A
GABA Plasma Membrane Transport Proteins
Receptors, GABA-B
GABA Uptake Inhibitors
GABA-A Receptor Antagonists
Baclofen
Muscimol
Bicuculline
Picrotoxin
Phosphinic Acids
4-Aminobutyrate Transaminase
GABA-B Receptor Antagonists
Neural Inhibition
Glutamate Decarboxylase
Neurons
Inhibitory Postsynaptic Potentials
Patch-Clamp Techniques
Synaptic Transmission
Diazepam
Vigabatrin
Vesicular Inhibitory Amino Acid Transport Proteins
Rats, Sprague-Dawley
Isonicotinic Acids
Pregnanolone
Hippocampus
Glutamic Acid
Aminobutyrates
Synapses
Benzodiazepines
Protein Subunits
Organic Anion Transporters
Interneurons
Sodium Oxybate
Flunitrazepam
Neurotransmitter Uptake Inhibitors
Membrane Potentials
Strychnine
Glycine
Neurotransmitter Agents
Electrophysiology
Flumazenil
Presynaptic Terminals
Crotonates
Dose-Response Relationship, Drug
Excitatory Postsynaptic Potentials
Rats, Wistar
Receptors, Glycine
Excitatory Amino Acid Antagonists
Convulsants
Glycine Agents
Action Potentials
3-Mercaptopropionic Acid
Pyramidal Cells
Cerebral Cortex
Xenopus laevis
Pregnanediones
Carbolines
6-Cyano-7-nitroquinoxaline-2,3-dione
Cerebellum
Etomidate
Anti-Anxiety Agents
Organophosphorus Compounds
Sodium Potassium Chloride Symporter Inhibitors
Ethanol
Solute Carrier Family 12, Member 2
Isoxazoles
Receptors, Presynaptic
Membrane Transport Proteins
Brain
Oocytes
Evoked Potentials
Tetrodotoxin
Chlordiazepoxide
Cells, Cultured
Taurine
Anisoles
Synaptosomes
Microinjections
Iontophoresis
Seizures
Succinate-Semialdehyde Dehydrogenase
Oximes
beta-Alanine
Central Nervous System Depressants
Neocortex
Dendrites
Pentylenetetrazole
Globus Pallidus
Hypnotics and Sedatives
Allylglycine
Drug Interactions
Aminocaproates
Chloride Channels
Anesthetics
Microdialysis
Retina
Allosteric Regulation
Retinal Bipolar Cells
Organ Culture Techniques
Dopamine
Ventral Tegmental Area
Parvalbumins
Kainic Acid
Barbiturates
Spinal Cord
2-Amino-5-phosphonovalerate
Ion Channel Gating
Electrophysiological Phenomena
Anesthetics, General
Epilepsy
Carrier Proteins
Amacrine Cells
Immunohistochemistry
Nerve Endings
Bicyclo Compounds, Heterocyclic
Glutamates
Receptors, N-Methyl-D-Aspartate
Calcium
Dentate Gyrus
CA1 Region, Hippocampal
Miniature Postsynaptic Potentials
Clonazepam
Receptors, Glutamate
Dieldrin
Propofol
Synaptic Membranes
Symporters
Receptors, Neurotransmitter
Amygdala
N-Methylaspartate
Benzylamines
Hypothalamus
Sodium-Potassium-Chloride Symporters
Membrane Proteins
Gramicidin
Sodium Channel Blockers
Mice, Knockout
Neuronal Plasticity
Medulla Oblongata
Models, Neurological
Epilepsy, Absence
Rats, Long-Evans
Brain Chemistry
Solitary Nucleus
Anesthetics, Intravenous
Nerve Net
Corpus Striatum
Lorazepam
Receptors, Metabotropic Glutamate
Thalamic Nuclei
Glutamine
Ion Channels
Reticular Formation
Xenopus
Substantia Nigra
Olfactory Bulb
Pilocarpine
Analysis of Variance
Mice, Transgenic
Potassium
Rana ridibunda
Autoreceptors
Excitatory Amino Acids
Binding Sites
Prefrontal Cortex
Brain Stem
G Protein-Coupled Inwardly-Rectifying Potassium Channels
Flurothyl
Pregnanes
Why are there so few resistance-associated mutations in insecticide target genes? (1/3892)
The genes encoding the three major targets of conventional insecticides are: Rdl, which encodes a gamma-aminobutyric acid receptor subunit (RDL); para, which encodes a voltage-gated sodium channel (PARA); and Ace, which encodes insect acetylcholinesterase (AChE). Interestingly, despite the complexity of the encoded receptors or enzymes, very few amino acid residues are replaced in different resistant insects: one within RDL, two within PARA and three or more within AChE. Here we examine the possible reasons underlying this extreme conservation by looking at the aspects of receptor and/or enzyme function that may constrain replacements to such a limited number of residues. (+info)Somatic recording of GABAergic autoreceptor current in cerebellar stellate and basket cells. (2/3892)
Patch-clamp recordings were performed from stellate and basket cells in rat cerebellar slices. Under somatic voltage clamp, short depolarizing pulses were applied to elicit action potentials in the axon. After the action potential, a bicuculline- and Cd2+-sensitive current transient was observed. A similar response was obtained when eliciting axonal firing by extracellular stimulation. With an isotonic internal Cl- solution, the peak amplitude of this current varied linearly with the holding potential, yielding an extrapolated reversal potential of -20 to 0 mV. Unlike synaptic or autaptic GABAergic currents obtained in the same preparation, the current transient had a slow rise-time and a low variability between trials. This current was blocked when 10 mM BAPTA was included in the recording solution. In some experiments, the current transient elicited axonal action potentials. The current transient was reliably observed in animals aged 12-15 d, with a mean amplitude of 82 pA at -70 mV, but was small and rare in the age group 29-49 d. Numerical simulations could account for all properties of the current transient by assuming that an action potential activates a distributed GABAergic conductance in the axon. The actual conductance is probably restricted to release sites, with an estimated mean presynaptic current response of 10 pA per site (-70 mV, age 12-15 d). We conclude that in developing rats, stellate and basket cell axons have a high density of GABAergic autoreceptors and that a sizable fraction of the corresponding current can be measured from the soma. (+info)Peripheral-type benzodiazepine receptor (PBR) in human breast cancer: correlation of breast cancer cell aggressive phenotype with PBR expression, nuclear localization, and PBR-mediated cell proliferation and nuclear transport of cholesterol. (3/3892)
Aberrant cell proliferation and increased invasive and metastatic behavior are hallmarks of the advancement of breast cancer. Numerous studies implicate a role for cholesterol in the mechanisms underlying cell proliferation and cancer progression. The peripheral-type benzodiazepine receptor (PBR) is an Mr 18,000 protein primarily localized to the mitochondria. PBR mediates cholesterol transport across the mitochondrial membranes in steroidogenic cells. A role for PBR in the regulation of tumor cell proliferation has also been shown. In this study, we examined the expression, characteristics, localization, and function of PBR in a battery of human breast cancer cell lines differing in their invasive and chemotactic potential as well as in several human tissue biopsies. Expression of PBR ligand binding and mRNA was dramatically increased in the highly aggressive cell lines, such as MDA-231, relative to nonaggressive cell lines, such as MCF-7. PBR was also found to be expressed at high levels in aggressive metastatic human breast tumor biopsies compared with normal breast tissues. Subcellular localization with both antibodies and a fluorescent PBR drug ligand revealed that PBR from the MDA-231 cell line as well as from aggressive metastatic human breast tumor biopsies localized primarily in and around the nucleus. This localization is in direct contrast to the largely cytoplasmic localization seen in MCF-7 cells, normal breast tissue, and to the typical mitochondrial localization seen in mouse tumor Leydig cells. Pharmacological characterization of the receptor and partial nucleotide sequencing of PBR cDNA revealed that the MDA-231 PBR is similar, although not identical, to previously described PBR. Addition of high affinity PBR drug ligands to MDA-231 cells increased the incorporation of bromodeoxyuridine into the cells in a dose-dependent manner, suggesting a role for PBR in the regulation of MDA-231 cell proliferation. Cholesterol uptake into isolated MDA-231 nuclei was found to be 30% greater than into MCF-7 nuclei. High-affinity PBR drug ligands regulated the levels of cholesterol present in MDA-231 nuclei but not in MCF-7. In addition, the PBR-dependent MDA-231 cell proliferation was found to highly correlate (r = -0.99) with the PBR-mediated changes in nuclear membrane cholesterol levels. In conclusion, these data suggest that PBR expression, nuclear localization, and PBR-mediated cholesterol transport into the nucleus are involved in human breast cancer cell proliferation and aggressive phenotype expression, thus participating in the advancement of the disease. (+info)Synaptic activation of GABAA receptors induces neuronal uptake of Ca2+ in adult rat hippocampal slices. (4/3892)
Synaptically evoked transmembrane movements of Ca2+ in the adult CNS have almost exclusively been attributed to activation of glutamate receptor channels and the consequent triggering of voltage-gated calcium channels (VGCCs). Using microelectrodes for measuring free extracellular Ca2+ ([Ca2+]o) and extracellular space (ECS) volume, we show here for the first time that synaptic stimulation of gamma-aminobutyric acid-A (GABAA) receptors can result in a decrease in [Ca2+]o in adult rat hippocampal slices. High-frequency stimulation (100-200 Hz, 0.4-0.5 s) applied in stratum radiatum close (+info)Retinal input induces three firing patterns in neurons of the superficial superior colliculus of neonatal rats. (5/3892)
By using an in vitro isolated brain stem preparation, we recorded extracellular responses to electrical stimulation of the optic tract (OT) from 71 neurons in the superficial superior colliculus (SC) of neonatal rats (P1-13). At postnatal day 1 (P1), all tested neurons (n = 10) already received excitatory input from the retina. Sixty-nine (97%) superficial SC neurons of neonatal rats showed three response patterns to OT stimulation, which depended on stimulus intensity. A weak stimulus evoked only one spike that was caused by activation of non-N-methyl-D-aspartate (NMDA) glutamate receptors. A moderate stimulus elicited a short train (<250 ms) of spikes, which was induced by activation of both NMDA and non-NMDA receptors. A strong stimulus gave rise to a long train (>300 ms) of spikes, which was associated with additional activation of L-type high-threshold calcium channels. The long train firing pattern could also be induced either by temporal summation of retinal inputs or by blocking gamma-aminobutyric acid-A receptors. Because retinal ganglion cells show synchronous bursting activity before eye opening at P14, the retinotectal inputs appear to be sufficient to activate L-type calcium channels in the absence of pattern vision. Therefore activation of L-type calcium channels is likely to be an important source for calcium influx into SC neurons in neonatal rats. (+info)Postnatal development of hippocampal dentate granule cell gamma-aminobutyric acidA receptor pharmacological properties. (6/3892)
Postnatal development of hippocampal dentate granule cell gamma-aminobutyric acidA (GABAA) receptor pharmacological properties was studied. Granule cells were acutely isolated from hippocampi of 7- to 14- and 45- to 52-day-old rats, and whole cell patch-clamp recordings were obtained. The sensitivity of GABAA receptors to GABA and modulation of GABAA receptor currents by benzodiazepines (BZ), zinc, furosemide, and loreclezole was studied. Multiple changes in the pharmacological properties of dentate granule-cell GABAA receptors occurred during the first 52 days of postnatal development: GABA-evoked maximal current increased with postnatal age; GABAA receptors changed from BZ type 3 in young rats to BZ type 1 in adult rats; furosemide and zinc inhibited GABAA receptor currents in young rats but not in adult rats; the fraction of cells that expressed loreclezole-sensitive GABAA receptors increased with postnatal age. These findings suggest that dentate granule cells in young and adult animals express pharmacologically distinct GABAA receptors and that the postnatal development of these receptors is prolonged, lasting at least 45 days. Comparison with the previously reported pharmacological properties of GABAA receptors on dentate granule cells acutely isolated from hippocampi of 28- to 35-day-old rats suggests that receptors expressed at that age have properties intermediate between young and adult rats. (+info)Dopamine receptor subtypes modulate olfactory bulb gamma-aminobutyric acid type A receptors. (7/3892)
The gamma-aminobutyric acid type A (GABAA) receptor is the predominant Cl- channel protein mediating inhibition in the olfactory bulb and elsewhere in the mammalian brain. The olfactory bulb is rich in neurons containing both GABA and dopamine. Dopamine D1 and D2 receptors are also highly expressed in this brain region with a distinct and complementary distribution pattern. This distribution suggests that dopamine may control the GABAergic inhibitory processing of odor signals, possibly via different signal-transduction mechanisms. We have observed that GABAA receptors in the rat olfactory bulb are differentially modulated by dopamine in a cell-specific manner. Dopamine reduced the currents through GABA-gated Cl- channels in the interneurons, presumably granule cells. This action was mediated via D1 receptors and involved phosphorylation of GABAA receptors by protein kinase A. Enhancement of GABA responses via activation of D2 dopamine receptors and phosphorylation of GABAA receptors by protein kinase C was observed in mitral/tufted cells. Decreasing or increasing the binding affinity for GABA appears to underlie the modulatory effects of dopamine via distinct receptor subtypes. This dual action of dopamine on inhibitory GABAA receptor function in the rat olfactory bulb could be instrumental in odor detection and discrimination, olfactory learning, and ultimately odotopic memory formation. (+info)Regional differences in the inhibition of mouse in vivo [3H]Ro 15-1788 binding reflect selectivity for alpha 1 versus alpha 2 and alpha 3 subunit-containing GABAA receptors. (8/3892)
The benzodiazepines flunitrazepam, diazepam, and Ro 15-1788 and the beta-carboline DMCM bind with equivalent affinity to the benzodiazepine binding site of GABAA receptors containing different alpha subunits (i.e., alpha 1, alpha 2, alpha 3, or alpha 5); whereas, the triazolopyridazine CL 218,872 and imidazopyridine zolpidem have higher affinity for alpha 1 subunit-containing GABAA receptors. In the present study, the in vivo binding of [3H]Ro 15-1788 in mouse cerebellum and spinal cord was used to establish the occupancy of the benzodiazepine binding site of GABAA receptors containing primarily alpha 1 and alpha 2/alpha 3 subunits, respectively. Thus, the nonselective compounds flunitrazepam, diazepam, and DMCM all produced a similar inhibition of binding in cerebellum and spinal cord (respective ID50 values of 0.2 to 0.3 mg/kg, 2 mg/kg, and 10 mg/kg i.p.); whereas, the alpha 1 selective compounds CL 218,872 and zolpidem were more potent at inhibiting [3H]Ro 15-1788 binding in the cerebellum (ID50 values 4.5 mg/kg and 10 mg/kg i.p.) compared to the spinal cord (ID50 values 12 mg/kg and > 30 mg/kg i.p.). Thus, the reduction of in vivo f[3H]Ro 15-1788 binding in tissues containing alpha 1 and alpha 2/alpha 3 receptor populations reflects the in vitro affinities of subtype selective compounds and should help to interpret the behavioral profile of such compounds. (+info)There are many different types of seizures, each with its own unique set of symptoms. Some common types of seizures include:
1. Generalized seizures: These seizures affect both sides of the brain and can cause a range of symptoms, including convulsions, loss of consciousness, and muscle stiffness.
2. Focal seizures: These seizures affect only one part of the brain and can cause more specific symptoms, such as weakness or numbness in a limb, or changes in sensation or vision.
3. Tonic-clonic seizures: These seizures are also known as grand mal seizures and can cause convulsions, loss of consciousness, and muscle stiffness.
4. Absence seizures: These seizures are also known as petit mal seizures and can cause a brief loss of consciousness or staring spell.
5. Myoclonic seizures: These seizures can cause sudden, brief muscle jerks or twitches.
6. Atonic seizures: These seizures can cause a sudden loss of muscle tone, which can lead to falls or drops.
7. Lennox-Gastaut syndrome: This is a rare and severe form of epilepsy that can cause multiple types of seizures, including tonic, atonic, and myoclonic seizures.
Seizures can be diagnosed through a combination of medical history, physical examination, and diagnostic tests such as electroencephalography (EEG) or imaging studies. Treatment for seizures usually involves anticonvulsant medications, but in some cases, surgery or other interventions may be necessary.
Overall, seizures are a complex and multifaceted symptom that can have a significant impact on an individual's quality of life. It is important to seek medical attention if you or someone you know is experiencing seizures, as early diagnosis and treatment can help to improve outcomes and reduce the risk of complications.
There are many different types of epilepsy, each with its own unique set of symptoms and characteristics. Some common forms of epilepsy include:
1. Generalized Epilepsy: This type of epilepsy affects both sides of the brain and can cause a range of seizure types, including absence seizures, tonic-clonic seizures, and atypical absence seizures.
2. Focal Epilepsy: This type of epilepsy affects only one part of the brain and can cause seizures that are localized to that area. There are several subtypes of focal epilepsy, including partial seizures with complex symptoms and simple partial seizures.
3. Tonic-Clonic Epilepsy: This type of epilepsy is also known as grand mal seizures and can cause a loss of consciousness, convulsions, and muscle stiffness.
4. Lennox-Gastaut Syndrome: This is a rare and severe form of epilepsy that typically develops in early childhood and can cause multiple types of seizures, including tonic, atonic, and myoclonic seizures.
5. Dravet Syndrome: This is a rare genetic form of epilepsy that typically develops in infancy and can cause severe, frequent seizures.
6. Rubinstein-Taybi Syndrome: This is a rare genetic disorder that can cause intellectual disability, developmental delays, and various types of seizures.
7. Other forms of epilepsy include Absence Epilepsy, Myoclonic Epilepsy, and Atonic Epilepsy.
The symptoms of epilepsy can vary widely depending on the type of seizure disorder and the individual affected. Some common symptoms of epilepsy include:
1. Seizures: This is the most obvious symptom of epilepsy and can range from mild to severe.
2. Loss of consciousness: Some people with epilepsy may experience a loss of consciousness during a seizure, while others may remain aware of their surroundings.
3. Confusion and disorientation: After a seizure, some people with epilepsy may feel confused and disoriented.
4. Memory loss: Seizures can cause short-term or long-term memory loss.
5. Fatigue: Epilepsy can cause extreme fatigue, both during and after a seizure.
6. Emotional changes: Some people with epilepsy may experience emotional changes, such as anxiety, depression, or mood swings.
7. Cognitive changes: Epilepsy can affect cognitive function, including attention, memory, and learning.
8. Sleep disturbances: Some people with epilepsy may experience sleep disturbances, such as insomnia or sleepiness.
9. Physical symptoms: Depending on the type of seizure, people with epilepsy may experience physical symptoms such as muscle weakness, numbness or tingling, and sensory changes.
10. Social isolation: Epilepsy can cause social isolation due to fear of having a seizure in public or stigma associated with the condition.
It's important to note that not everyone with epilepsy will experience all of these symptoms, and some people may have different symptoms depending on the type of seizure they experience. Additionally, some people with epilepsy may experience additional symptoms not listed here.
The diagnosis of absence epilepsy is typically made based on a combination of clinical findings, including:
-A history of recurrent brief loss of awareness or staring spells
-Normal neurological examination between episodes
-Abnormal EEG activity during seizures (spikes or sharp waves)
Treatment for absence epilepsy usually involves medication, such as ethosuximide, valproic acid, or lamotrigine. In some cases, surgery may be considered if medications are ineffective or have significant side effects.
It is important to note that absence epilepsy can be a challenging condition to diagnose and treat, as the spells can be difficult to distinguish from other conditions such as daydreaming or attention deficit hyperactivity disorder (ADHD).
There are two main types of status epilepticus:
1. Generalized status epilepticus: This type affects the entire brain and is characterized by severe convulsions, loss of consciousness, and muscle stiffness.
2. Focal status epilepticus: This type affects only one part of the brain and can cause more subtle symptoms, such as weakness or numbness in a limb, speech difficulties, or confusion.
The diagnosis of status epilepticus is based on clinical findings, medical history, and electroencephalography (EEG) recordings. Treatment typically involves prompt administration of anticonvulsant medications, such as benzodiazepines or barbiturates, to control seizures and prevent further brain damage. In severe cases, sedation, mechanical ventilation, or anesthesia may be required to support the patient's vital functions.
The prognosis for status epilepticus depends on several factors, including the underlying cause, the severity of the seizure, and the promptness and effectiveness of treatment. In general, the earlier the treatment is initiated, the better the outcome. However, long-term neurological and cognitive deficits can occur in some cases.
Preventive measures for status epilepticus include proper management of underlying conditions that may trigger seizures, such as epilepsy or head trauma, and avoiding triggers like alcohol or drugs. Additionally, prompt medical attention should be sought if seizure warning signs are present, such as changes in sensation, confusion, or convulsions.
1) They share similarities with humans: Many animal species share similar biological and physiological characteristics with humans, making them useful for studying human diseases. For example, mice and rats are often used to study diseases such as diabetes, heart disease, and cancer because they have similar metabolic and cardiovascular systems to humans.
2) They can be genetically manipulated: Animal disease models can be genetically engineered to develop specific diseases or to model human genetic disorders. This allows researchers to study the progression of the disease and test potential treatments in a controlled environment.
3) They can be used to test drugs and therapies: Before new drugs or therapies are tested in humans, they are often first tested in animal models of disease. This allows researchers to assess the safety and efficacy of the treatment before moving on to human clinical trials.
4) They can provide insights into disease mechanisms: Studying disease models in animals can provide valuable insights into the underlying mechanisms of a particular disease. This information can then be used to develop new treatments or improve existing ones.
5) Reduces the need for human testing: Using animal disease models reduces the need for human testing, which can be time-consuming, expensive, and ethically challenging. However, it is important to note that animal models are not perfect substitutes for human subjects, and results obtained from animal studies may not always translate to humans.
6) They can be used to study infectious diseases: Animal disease models can be used to study infectious diseases such as HIV, TB, and malaria. These models allow researchers to understand how the disease is transmitted, how it progresses, and how it responds to treatment.
7) They can be used to study complex diseases: Animal disease models can be used to study complex diseases such as cancer, diabetes, and heart disease. These models allow researchers to understand the underlying mechanisms of the disease and test potential treatments.
8) They are cost-effective: Animal disease models are often less expensive than human clinical trials, making them a cost-effective way to conduct research.
9) They can be used to study drug delivery: Animal disease models can be used to study drug delivery and pharmacokinetics, which is important for developing new drugs and drug delivery systems.
10) They can be used to study aging: Animal disease models can be used to study the aging process and age-related diseases such as Alzheimer's and Parkinson's. This allows researchers to understand how aging contributes to disease and develop potential treatments.
Epilepsy, temporal lobe can cause a variety of seizure types, including:
1. Partial seizures: These are seizures that affect only one part of the brain, such as the temporal lobe.
2. Simple partial seizures: These are seizures that do not involve convulsions or loss of consciousness.
3. Complex partial seizures: These are seizures that involve impaired awareness or altered perception, and may involve convulsions or muscle stiffness.
4. Tonic-clonic seizures (formerly known as grand mal seizures): These are seizures that involve convulsions, loss of consciousness, and muscle stiffness.
The symptoms of epilepsy, temporal lobe can vary depending on the location of the seizure focus within the temporal lobe and the individual's age, but may include:
1. Auras (sensory disturbances such as flashing lights or unusual smells)
2. Confusion or disorientation
3. Memory loss or difficulty with memory
4. Emotional changes (such as fear, anxiety, or euphoria)
5. Speech difficulties
6. Muscle stiffness or weakness
7. Coordination problems
8. Vision changes (such as blurred vision or double vision)
9. Hearing changes (such as ringing in the ears)
10. Numbness or tingling sensations
Epilepsy, temporal lobe is typically diagnosed using a combination of medical history, physical examination, and diagnostic tests such as electroencephalography (EEG) or magnetic resonance imaging (MRI). Treatment options may include medication, surgery, or lifestyle modifications.
There are several types of ataxia, each with different symptoms and causes. Some common forms of ataxia include:
1. Spinocerebellar ataxia (SCA): This is the most common form of ataxia and is caused by a degeneration of the cerebellum and spinal cord. It can cause progressive weakness, loss of coordination, and difficulty with speaking and swallowing.
2. Friedreich's ataxia: This is the second most common form of ataxia and is caused by a deficiency of vitamin E in the body. It can cause weakness in the legs, difficulty walking, and problems with speech and language.
3. Ataxia-telangiectasia (AT): This is a rare form of ataxia that is caused by a gene mutation. It can cause progressive weakness, loss of coordination, and an increased risk of developing cancer.
4. Acute cerebellar ataxia: This is a sudden and temporary form of ataxia that can be caused by a variety of factors such as infections, injuries, or certain medications.
5. Drug-induced ataxia: Certain medications can cause ataxia as a side effect.
6. Vitamin deficiency ataxia: Deficiencies in vitamins such as vitamin B12 or folate can cause ataxia.
7. Metabolic disorders: Certain metabolic disorders such as hypothyroidism, hyperthyroidism, and hypoglycemia can cause ataxia.
8. Stroke or brain injury: Ataxia can be a result of a stroke or brain injury.
9. Multiple system atrophy (MSA): This is a rare progressive neurodegenerative disorder that can cause ataxia, parkinsonism, and autonomic dysfunction.
10. Spinocerebellar ataxia (SCA): This is a group of rare genetic disorders that can cause progressive cerebellar ataxia, muscle wasting, and other signs and symptoms.
It's important to note that this is not an exhaustive list and there may be other causes of ataxia not mentioned here. If you suspect you or someone you know may have ataxia, it is important to consult a healthcare professional for proper diagnosis and treatment.
* Anxiety
* Depression
* Fatigue
* Insomnia
* Muscle and bone pain
* Nausea and vomiting
* Seizures (in severe cases)
* Sweating
* Tremors
The specific symptoms of substance withdrawal syndrome can vary depending on the substance being withdrawn from, but some common symptoms include:
* Alcohol: tremors, anxiety, insomnia, nausea and vomiting, headaches, and seizures
* Opioids: withdrawal symptoms can include anxiety, muscle aches, sweating, nausea and vomiting, diarrhea, and depression
* Benzodiazepines: withdrawal symptoms can include anxiety, insomnia, tremors, and seizures
The diagnosis of substance withdrawal syndrome is typically made based on the patient's history of substance use and the presence of withdrawal symptoms. A healthcare provider may also order laboratory tests to rule out other conditions that may be causing the symptoms. Treatment for substance withdrawal syndrome usually involves supportive care, such as rest, hydration, and pain management, as well as medication to manage withdrawal symptoms. In some cases, medical professionals may also recommend a gradual tapering of the substance over a period of time to minimize withdrawal symptoms.
It is important for individuals who are experiencing withdrawal symptoms to seek medical attention as soon as possible, as untreated withdrawal can lead to serious complications, such as seizures and dehydration. With appropriate treatment, most individuals with substance withdrawal syndrome can recover fully and successfully overcome their addiction.
The term "schizophrenia" was first used by the Swiss psychiatrist Eugen Bleuler in 1908 to describe the splitting of mental functions, which he believed was a key feature of the disorder. The word is derived from the Greek words "schizein," meaning "to split," and "phrenos," meaning "mind."
There are several subtypes of schizophrenia, including:
1. Paranoid Schizophrenia: Characterized by delusions of persecution and suspicion, and a tendency to be hostile and defensive.
2. Hallucinatory Schizophrenia: Characterized by hearing voices or seeing things that are not there.
3. Disorganized Schizophrenia: Characterized by disorganized thinking and behavior, and a lack of motivation or interest in activities.
4. Catatonic Schizophrenia: Characterized by immobility, mutism, and other unusual movements or postures.
5. Undifferentiated Schizophrenia: Characterized by a combination of symptoms from the above subtypes.
The exact cause of schizophrenia is still not fully understood, but it is believed to involve a combination of genetic, environmental, and neurochemical factors. It is important to note that schizophrenia is not caused by poor parenting or a person's upbringing.
There are several risk factors for developing schizophrenia, including:
1. Genetics: A person with a family history of schizophrenia is more likely to develop the disorder.
2. Brain chemistry: Imbalances in neurotransmitters such as dopamine and serotonin have been linked to schizophrenia.
3. Prenatal factors: Factors such as maternal malnutrition or exposure to certain viruses during pregnancy may increase the risk of schizophrenia in offspring.
4. Childhood trauma: Traumatic events during childhood, such as abuse or neglect, have been linked to an increased risk of developing schizophrenia.
5. Substance use: Substance use has been linked to an increased risk of developing schizophrenia, particularly cannabis and other psychotic substances.
There is no cure for schizophrenia, but treatment can help manage symptoms and improve quality of life. Treatment options include:
1. Medications: Antipsychotic medications are the primary treatment for schizophrenia. They can help reduce positive symptoms such as hallucinations and delusions, and negative symptoms such as a lack of motivation or interest in activities.
2. Therapy: Cognitive-behavioral therapy (CBT) and other forms of talk therapy can help individuals with schizophrenia manage their symptoms and improve their quality of life.
3. Social support: Support from family, friends, and support groups can be an important part of the treatment plan for individuals with schizophrenia.
4. Self-care: Engaging in activities that bring pleasure and fulfillment, such as hobbies or exercise, can help individuals with schizophrenia improve their overall well-being.
It is important to note that schizophrenia is a complex condition, and treatment should be tailored to the individual's specific needs and circumstances. With appropriate treatment and support, many people with schizophrenia are able to lead fulfilling lives and achieve their goals.
Hypothermia can be mild, moderate, or severe. Mild hypothermia is characterized by shivering and a body temperature of 95 to 97 degrees Fahrenheit (32 to 36.1 degrees Celsius). Moderate hypothermia has a body temperature of 82 to 94 degrees Fahrenheit (28 to 34 degrees Celsius), and the person may appear lethargic, drowsy, or confused. Severe hypothermia is characterized by a body temperature below 82 degrees Fahrenheit (28 degrees Celsius) and can lead to coma and even death if not treated promptly.
Treatment for hypothermia typically involves warming the person up slowly, using blankets or heating pads, and providing warm fluids to drink. In severe cases, medical professionals may use a specialized warm water bath or apply warm packs to specific areas of the body.
Preventing hypothermia is important, especially in cold weather conditions. This can be done by dressing appropriately for the weather, staying dry and avoiding wet clothing, eating regularly to maintain energy levels, and seeking shelter if you become stranded or lost. It's also essential to recognize the signs of hypothermia early on so that treatment can begin promptly.
Types of Malformations of Cortical Development:
There are several types of malformations of cortical development, including:
1. Cerebral palsy: a group of disorders that affect movement, balance, and posture, often resulting from brain damage during fetal development or birth.
2. Hydrocephalus: a condition in which there is an abnormal accumulation of cerebrospinal fluid (CSF) in the brain, leading to increased intracranial pressure and enlargement of the head.
3. Microcephaly: a condition in which the brain and skull are smaller than normal, often resulting in developmental delays, intellectual disability, and seizures.
4. Macrocephaly: a condition in which the brain and skull are larger than normal, often resulting from an overproduction of CSF or a brain tumor.
5. Cortical dysplasia: a condition in which there is abnormal development of the cerebral cortex, leading to problems with movement, cognition, and behavior.
6. Fetal alcohol spectrum disorders (FASD): a group of conditions that result from exposure to alcohol during fetal development, often causing malformations of the cerebral cortex and other brain structures.
7. Genetic mutations: some genetic mutations can lead to malformations of cortical development, such as those caused by maternal infection or exposure to certain medications.
8. Infections during pregnancy: certain infections, such as rubella or toxoplasmosis, can cause malformations of cortical development if contracted during pregnancy.
9. Traumatic brain injury: a head injury during fetal development or early childhood can disrupt normal cortical development and lead to developmental delays and cognitive impairments.
10. Exposure to toxins: exposure to certain toxins, such as lead or pesticides, during fetal development can damage the developing brain and result in malformations of cortical development.
These are just a few examples of conditions that can cause malformations of cortical development. It's important to note that many of these conditions can be diagnosed through imaging studies such as MRI or CT scans, and some may require specialized testing or monitoring throughout childhood. Early detection and intervention can help improve outcomes for children with these conditions.
Types of Hypothalamic Diseases:
1. Hypothalamic hamartoma: A benign tumor that develops in the hypothalamus and can cause a variety of symptoms such as seizures, obesity, and developmental delays.
2. Hypothalamic glioma: A malignant tumor that arises in the hypothalamus and can cause similar symptoms to hypothalamic hamartoma.
3. Hypothalamic malformations: Congenital abnormalities that affect the development of the hypothalamus, leading to various neurological symptoms such as seizures, intellectual disability, and behavioral problems.
4. Hypothalamic infarction: A condition where there is a lack of blood flow to the hypothalamus, leading to damage to the tissue and potentially causing a range of symptoms including stroke-like symptoms.
5. Hypothalamic lesions: Damage to the hypothalamus caused by traumatic brain injury, infection, or other factors, which can lead to a range of neurological symptoms.
Symptoms of Hypothalamic Diseases:
The symptoms of hypothalamic diseases can vary depending on the specific condition and the severity of the damage to the hypothalamus. Some common symptoms include:
* Seizures
* Headaches
* Vision problems
* Balance and coordination difficulties
* Weight changes (gain or loss)
* Sleep disturbances
* Mood changes (depression, anxiety)
* Behavioral problems (aggression, irritability)
* Intellectual disability
Diagnosis of Hypothalamic Diseases:
Diagnosing hypothalamic diseases can be challenging and may require a range of tests and evaluations. These may include:
1. Physical examination and medical history: A thorough evaluation of the patient's symptoms, medical history, and physical condition.
2. Imaging tests: Such as CT or MRI scans to visualize the brain and identify any structural abnormalities or lesions in the hypothalamus.
3. Blood tests: To check for hormone levels and other markers that can help diagnose specific conditions.
4. EEG and other neurological tests: To evaluate the patient's neurological function and identify any potential seizure activity or other abnormalities.
5. Genetic testing: If the condition is suspected to be inherited, genetic testing may be performed to identify mutations or variations in genes that can contribute to hypothalamic diseases.
Treatment of Hypothalamic Diseases:
The treatment of hypothalamic diseases depends on the specific condition and the severity of the symptoms. Some common treatments include:
1. Medications: Such as anticonvulsants, hormone replacement therapy, and pain management medications to control seizures, hormonal imbalances, and pain.
2. Hormone replacement therapy: To replace hormones that are deficient or imbalanced.
3. Surgery: May be necessary to remove a tumor or repair a structural abnormality in the hypothalamus.
4. Lifestyle modifications: Such as changes to diet, exercise, and sleep habits to manage symptoms and improve quality of life.
5. Rehabilitation therapy: To help regain lost functions and improve daily living skills.
Prognosis of Hypothalamic Diseases:
The prognosis for hypothalamic diseases varies depending on the specific condition and the severity of the symptoms. Some conditions may have a good prognosis with appropriate treatment, while others may have a poorer outcome. In general, early diagnosis and treatment can improve the chances of a better outcome.
Living with Hypothalamic Diseases:
Living with a hypothalamic disease can be challenging and may require significant lifestyle modifications and ongoing medical care. However, with the right treatment and support, many people are able to manage their symptoms and improve their quality of life. Some tips for living with a hypothalamic disease include:
1. Educate yourself about your condition and its management.
2. Work closely with your healthcare provider to develop a personalized treatment plan.
3. Make lifestyle modifications such as changes to diet, exercise, and sleep habits.
4. Join a support group to connect with others who are living with similar conditions.
5. Seek mental health support if needed to cope with the emotional impact of the condition.
In conclusion, hypothalamic diseases can have a significant impact on quality of life, but with early diagnosis and appropriate treatment, many people are able to manage their symptoms and improve their outcomes. It is important to work closely with a healthcare provider to develop a personalized treatment plan and make lifestyle modifications as needed. With the right support and resources, it is possible to live a fulfilling life with a hypothalamic disease.
GABA receptor
GABA receptor agonist
Ionotropic GABA receptor
GABA receptor antagonist
Gaba type a receptor associated protein like 1
GABA transporter type 1
Gamma-Hydroxybutyric acid
Clobazam
GABBR1
GABRD
Anxiety
Topiramate
GABAA receptor negative allosteric modulator
Picrotoxin
Alcohol (drug)
Pitrazepin
Theories of general anaesthetic action
GABA transporter
Gamma-aminobutyric acid receptor subunit gamma-2
Convulsant
Bamaluzole
GABAA receptor positive allosteric modulator
Muscimol
Nicotinic acetylcholine receptor
Translocator protein
Afoxolaner
Glutamate receptor
Effects of alcohol on memory
Tutin (toxin)
Essential tremor
List of investigational anxiolytics
Quazepam
Levorphanol
Lormetazepam
Pre-Bötzinger complex
Talbutal
GABRA4
Psychological stress and sleep
CGP-7930
Histamine H3 receptor
Metabotropic glutamate receptor
Flumazenil
Motion perception
WNK1
Brain
Index of biochemistry articles
Kosmos 2044
Alcohol myopia
Cannabis use and trauma
GABRG1
Generalized anxiety disorder
Norepinephrine transporter
Cyclopyrrolones
Excitatory amino acid transporter 3
Calcineurin
Benzodiazepine overdose
Acyl-CoA-binding protein
Specific regulation of mechanical nociception by Gβ5 involves GABA-B receptors - PubMed
The effect of a GABA receptor agonist on sleep deficiency in a Fragile X syndrome mouse model | NIH Research Festival
Epilepsy and Seizures Medication: Anticonvulsants, Other, Anticonvulsants, Barbiturates, Anticonvulsants, Benzodiazepine,...
Mechanisms of Action, Resistance and Toxicity of Insecticides Targeting GABA Receptors
| Bentham Science
GABA(B) receptors at glutamatergic synapses in the rat striatum. - Department of Physiology, Anatomy and Genetics (DPAG)
Details for:
Epilepsy and GABA receptor agonists :
› WHO HQ Library catalog
Nanoscale alterations in GABA|sub|B|/sub| receptors and GIRK channel organization on the hippocampus of APP/PS1 mice. |...
Functional movements of the GABA type A receptor - Institut Pasteur
Modulation of GABAA receptor desensitization uncouples sleep onset and maintenance in Drosophila | Nature Neuroscience
NIMH » A Bench-to-Bedside Story: The Development of a Treatment for Postpartum Depression
PAR-14-234: National Cooperative Drug Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders, Drug or...
Diffusion barriers constrain receptors at synapses
Allosteric positive interaction of thymol with the GABA-A receptor in primary cultures of mouse cortical neurons
Antihyperalgesia by 2-GABA A receptors occurs via a genuine spinal action and does not involve supraspinal sites<...
Childhood absence epilepsy: MedlinePlus Genetics
The construction of a targeting vector for GABA̳A receptor [alpha]1 subunit gene disruption - Rare & Special e-Zone
PA-03-112: DEVELOPMENT AND APPLICATION OF PET AND SPECT LIGANDS FOR BRAIN IMAGING STUDIES (PHASED INNOVATION AWARD)
PA-06-018: Development of PET and SPECT Ligands for Brain Imaging (STTR [R41/R42])
Epilepsy and Seizures: Practice Essentials, Background, Pathophysiology
Neurologic Disease after Yellow Fever Vaccination, São Paulo, Brazil, 2017-2018 - Volume 27, Number 6-June 2021 - Emerging...
'Sticky' gene may help Valium calm nerves | National Institutes of Health ...
NIAAA Director's Statement before the House Committee on Appropriations Subcommittee on Labor, Health and Human Services,...
CounterACT Publications 2018 | National Institute of Neurological Disorders and Stroke
NIOSHTIC-2 Search Results - Full View
Molecules | Free Full-Text | Challenges, Applications, and Recent Advances of Protein-Ligand Docking in Structure-Based Drug...
Publications - William F. Simonds, M.D. - NIDDK
Publication Detail
Structure and dynamics of differential ligand binding in the human ρ-type GABAA receptor - PubMed
Subunit15
- The important resistant to dieldrin GABA receptor subunit (RDL) has been used to investigate insecticide sites of action using radioligands, electrophysiology and site-directed mutagenesis. (eurekaselect.com)
- Although this important subunit readily forms robust functional homomeric receptors when expressed, alternative splicing and RNA A-to-I editing can generate diverse forms of the receptor. (eurekaselect.com)
- However, the subunit composition of native GABA receptors remains unknown and studies to clarify this are needed. (eurekaselect.com)
- These observations indicate that the blocking drugs can produce allosteric changes in GABA A receptors, at least those containing this mutated β2 subunit. (jneurosci.org)
- Finally, both gabazine and bicuculline act as weak agonists for GABA A receptors containing the β2(Y157S) mutated subunit. (jneurosci.org)
- As shown for GABA(A)R, the excitatory glutamate receptor 2 subunit (GluA2) of the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) had lower mobility in both excitatory and inhibitory synapses but a higher residency time at excitatory synapses. (nih.gov)
- These drugs facilitate the function of pentameric GABA A receptors that exhibit widespread expression in all brain regions and large structural and pharmacological heterogeneity as a result of composition from a repertoire of 19 subunit variants. (aspetjournals.org)
- Most drugs, in long-term use and during withdrawal, have been associated with important modulations of the receptor subunit expression in brain-region-specific manner, participating in the mechanisms of tolerance and dependence. (aspetjournals.org)
- GABA A receptor αl subunit is the most widely expressed in the brain among at least 17 known subunits. (edu.hk)
- The present thesis work aimed at the construction of a replacement type of vector for a targeted disruption of the GABA A receptor αl subunit in mice. (edu.hk)
- The success of this construction will facilitate the ablation of αl subunit gene and provide a mouse model for the in vivo studies on GABA A receptor αl subunit. (edu.hk)
- For the construction of the targeting vector, a 13-kb DNA fragment containing the first two exons of mouse GABA A receptor al subunit was obtained from screening of a λ2001 based 129/Sv mouse genomic library. (edu.hk)
- Therefore, mice generated from these cell lines will have ablated GABA A receptor αl subunit. (edu.hk)
- Mutations in GABA A receptor subunit genes lead to production of altered subunit proteins that cannot form functional receptors, so fewer GABA A receptors are available. (medlineplus.gov)
- Influence of subunit configuration on the interaction of picrotoxin-site ligands with recombinant GABA(A) receptors. (bvsalud.org)
Subunits9
- We have studied the ability of alphaxalone (an anesthetic steroid) and pentobarbital (an anesthetic barbiturate) to directly activate recombinant GABA A receptors containing the α1, β2, and γ2L subunits. (jneurosci.org)
- Steroid gating was not affected when either of two mutated β2 subunits [β2(Y157S) and β2(Y205S)] are incorporated into the receptors, although these subunits greatly reduce the affinity of GABA binding. (jneurosci.org)
- Finally, at receptors containing α1β2(Y157S)γ2L subunits, both bicuculline and gabazine showed weak agonist activity and actually potentiated responses to alphaxalone. (jneurosci.org)
- To address this question, we studied the membrane diffusion of the γ-aminobutyric acid type A receptor (GABA(A)R) subunits clustered (γ2) or not (α5) at inhibitory synapses in rat hippocampal dissociated neurons. (nih.gov)
- This antihyperalgesia occurs mainly through GABA A receptors (GABA A Rs) containing 2 subunits (2-GABA A Rs). (illinois.edu)
- One key step to extend drug development related to GABA A receptors is likely to require deeper understanding of the adaptational mechanisms of neurons, receptors themselves with interacting proteins, and finally receptor subunits during drug action and in neuropsychiatric disease processes. (aspetjournals.org)
- Several genes associated with childhood absence epilepsy provide instructions for making pieces (subunits) of the GABA A receptor protein. (medlineplus.gov)
- Hirose S. Mutant GABA(A) receptor subunits in genetic (idiopathic) epilepsy. (medlineplus.gov)
- Its application in the case of brain mRNAs for the GABAA receptor is illustrated, including the production of receptor subunits and its chloride channel with characteristic pharmacology. (xenbase.org)
Agonists2
- Lancel, M. Role of GABAA receptors in the regulation of sleep: initial sleep responses to peripherally administered modulators and agonists. (nature.com)
- One of the main problems in clinical use of GABA A receptor agonists is the development of tolerance. (aspetjournals.org)
Inhibitory7
- Background: γ-Aminobutyric acid (GABA) receptors play a central role in fast inhibitory neurotransmission in insects. (eurekaselect.com)
- Furthermore, using a gephyrin dominant-negative approach, we showed that the increased residency time of γ2 at inhibitory synapses was due to receptor-scaffold interactions. (nih.gov)
- The γ-aminobutyric acid (GABA) type A receptor system, the main fast-acting inhibitory neurotransmitter system in the brain, is the pharmacological target for many drugs used clinically to treat, for example, anxiety disorders and epilepsy, and to induce and maintain sedation, sleep, and anesthesia. (aspetjournals.org)
- GABA A receptors mediate the major inhibitory synaptic transmission in the central nervous system, and form a number of binding sites for clinically important drugs such as benzodiazepines. (edu.hk)
- [5] Gamma-aminobutyric acid (GABA) and glycine, conversely, serve as the major inhibitory neurotransmitters. (nih.gov)
- GABA, for example, can account for approximately 40% of the inhibitory processing in the brain. (nih.gov)
- The day after drinking we get what we call a glutamate storm - so you've got much more glutamate binding and working in the brain and not enough of the inhibitory, calming brain chemical, gaba," Professor Currie said. (beyondblue.org.au)
Gamma-amin2
- Baclofen, a gamma-aminobutyric acid 'B-receptor' agonist, has long been used to treat spasticity from neurological diseases, at a dose of 30-90 mg/day. (clinicaltrials.gov)
- Investigation of gamma-aminobutyric acid (GABA) A receptors genes and migraine susceptibility. (cdc.gov)
Recombinant1
- Methods: We have reviewed studies on native and recombinant insect GABA-gated chloride channels, their interactions with ligands acting at orthosteric and allosteric sites and their interactions with insecticides. (eurekaselect.com)
Neurons1
- In the present work, we more closely examined the pharmacological action of thymol on the native GABAA receptor by using primary cultures of cortical neurons. (uchile.cl)
Neurotransmitter2
- The flux of neurotransmitter receptors in and out of synapses depends on receptor interaction with scaffolding molecules. (nih.gov)
- Functional expression in the Xenopus oocyte of messenger ribonucleic acids encoding brain neurotransmitter receptors: further characterisation of the implanted GABA receptor. (xenbase.org)
Chloride channels6
- Several classes of insecticides targeting insect GABA-gated chloride channels have been developed. (eurekaselect.com)
- Since some GABA receptor modulators act on L-glutamate-gated chloride channels, some comparisons are included. (eurekaselect.com)
- Results: The actions on GABA-gated chloride channels of polychlorocycloalkanes, cyclodienes, macrocyclic lactones, phenylpyrazoles, isoxazolines, and metadiamides are described and the mechanisms of action of members of these insecticide classes are addressed. (eurekaselect.com)
- Toxicity issues relating to insecticides targeting GABA-gated chloride channels are also addressed. (eurekaselect.com)
- An overview of all major insecticide classes targeting insect GABA-gated chloride channels has enhanced our understanding of these important receptors and their insecticide binding sites. (eurekaselect.com)
- GABA-A receptors control chloride channels formed by the receptor complex itself. (bvsalud.org)
GABAA Receptor3
- Recent studies have reported enhanced GABAA receptor-operated chloride channel activity and increased binding affinity of [3H]flunitrazepam in the presence of thymol. (uchile.cl)
- This direct effect was inhibited by competitive and non-competitive GABAA receptor antagonists. (uchile.cl)
- These results confirm that thymol is a positive allosteric modulator of the GABAA receptor. (uchile.cl)
Proteins2
- However, the crowd of transmembrane proteins and the rich cytoskeletal environment may constitute obstacles to the diffusion of receptors within the synapse. (nih.gov)
- GABA-B receptors act through G-proteins on several effector systems, are insensitive to bicuculline, and have a high affinity for L-baclofen. (bvsalud.org)
Bicuculline1
- The data are consistent with a model in which both gabazine and bicuculline act as allosteric inhibitors of channel opening for the GABA A receptor after binding to the GABA-binding site. (jneurosci.org)
Barbiturates3
- We conclude that the sites for binding steroids and barbiturates do not overlap with the GABA-binding site. (jneurosci.org)
- In particular, steroids and barbiturates are each able to directly gate the GABA A receptor channel (in the absence of GABA), and they can also enhance the activation produced by low concentrations of GABA. (jneurosci.org)
- These data indicate that steroids and barbiturates do not bind to the GABA-binding site when they directly gate the channel of the GABA A receptor. (jneurosci.org)
Functional1
- Smith, G.B. & Olsen, R.W. Functional domains of GABAA receptors. (nature.com)
Residues2
- We find that simulated binding impulses to varying clusters of GABA binding site residues produce channel opening, and that equivalent impulses to single GABA sites produce partial opening. (archives-ouvertes.fr)
- Accordingly, we have examined the ability of alphaxalone to gate mutated GABA A receptors, and we found that residues that are important in determining the binding affinity of GABA do not affect activation by steroids. (jneurosci.org)
Pharmacological2
- Pharmacological manipulation of these receptors has differential effects on sleep onset and sleep maintenance insomnia. (nature.com)
- More knowledge has been obtained on the mechanisms of GABA A receptor trafficking and cell surface expression and the processes that may contribute to tolerance, although their possible pharmacological regulation is not known. (aspetjournals.org)
Concentrations1
- Thymol enhanced GABA-induced (5 μM) chloride influx at concentrations lower than those exhibiting direct activity in the absence of GABA (EC50 = 12 μM and 135 μM, respectively). (uchile.cl)
Potentiation2
- For the sites involved in potentiation, however, the steroid-binding site and the barbiturate-binding site are distinct from each other and are also distinct from the GABA-binding site ( Macdonald and Olsen, 1993 ). (jneurosci.org)
- Previous work indicates that potentiation of these receptors in the spinal cord evokes profound antihyperalgesia also after systemic administration, but possible synergistic or antagonistic actions of supraspinal 2-GABA A Rs on spinal antihyperalgesia have not yet been addressed. (illinois.edu)
Genes1
- When associated with mutations in GABA A receptor or calcium channel genes, it seems to follow an autosomal dominant inheritance pattern, which means one copy of the altered gene in each cell is sufficient to increase the likelihood of the disorder. (medlineplus.gov)
Neurotransmitters1
- Chemical synaptic transmission primarily through the release of neurotransmitters from presynaptic neural cells to postsynaptic receptors. (nih.gov)
Mechanisms1
- Gottesmann, C. GABA mechanisms and sleep. (nature.com)
Regulation2
- Many lines of evidence indicate that GABA and GABA A receptors make important contributions to human sleep regulation. (nature.com)
- These experiments uncouple the regulation of sleep latency from that of sleep duration and suggest that the kinetics of GABA A receptor signaling dictate sleep latency. (nature.com)
Modulate2
- Various other compounds also bind to the GABA A receptor and can gate the channel or modulate channel function ( Macdonald and Olsen, 1993 ). (jneurosci.org)
- Zinc and copper modulate differentially the P2X receptor. (cdc.gov)
Membrane1
- The Xenopus oocyte is the only system currently available for the full expression of mRNAS encoding membrane receptors and ion channels. (xenbase.org)
Compounds1
- Using a pharmacophoric model that includes a hydrogen bond donor group as well as an aromatic ring with two aliphatic substituents, we propose to demonstrate the molecular essential features of these compounds to interact with GABAA receptors. (uchile.cl)
Type1
- We have performed a parallel tempering crankshaft motion Monte Carlo simulation on a model of the GABA type A receptor with the aim of exploring a wide variety of local conformational space. (archives-ouvertes.fr)
Mice2
- Here we generated two lines of GABA A R-mutated mice, which either lack 2-GABA A Rs specifically from the spinal cord, or, which express only benzodiazepine-insensitive 2-GABA A Rs at this site. (illinois.edu)
- However, antihyperalgesia by systemic HZ166 was reduced in both mutated mouse lines by about 60% and was virtually indistinguishable from that of global point-mutated mice, in which all 2-GABA A Rs were benzodiazepine insensitive. (illinois.edu)
Major1
- The major (2-dependent) component of GABA A R-mediated antihyperalgesia was therefore exclusively of spinal origin, whereas supraspinal 2-GABA A Rs had neither synergistic nor antagonistic effects on antihyperalgesia. (illinois.edu)
Brain2
- GABA activates a ligand-gated ion channel (the GABA A receptor), which underlies most rapid inhibition in the brain. (jneurosci.org)
- Alcohol targets two receptors in the brain, which send messages to our nervous system. (beyondblue.org.au)
Effects2
- Figure 6: CBZ specifically increases RDL desensitization and the A302S mutation prevents CBZ effects ( a ) Response to 90-s application of 100 μM GABA with variable doses of CBZ, recorded from oocytes expressing RDL held at −60 mV under voltage clamp. (nature.com)
- It is not known whether the same sites are involved in producing direct gating and in potentiating the effects of GABA. (jneurosci.org)
Specific1
- Our data further reveal that the confinement and the dwell time but not the diffusion coefficient report on the synapse specific sorting, trapping and accumulation of receptors. (nih.gov)
Studies1
- We are interested in defining the sites on the GABA A receptor that are involved in direct gating by anesthetics, and we have initiated studies of channel activation by alphaxalone (an anesthetic steroid analog) and pentobarbital (an anesthetic barbiturate). (jneurosci.org)
Competitive1
- It is a competitive antagonist for GABA-A receptors. (curehunter.com)
Specifically1
- Here we show that sleep is regulated by GABA in Drosophila and that a mutant GABA A receptor, Rdl A302S , specifically decreases sleep latency. (nature.com)